Opinion|Videos|July 5, 2024

Adverse Event Considerations for DARA-VRd in NDMM

Author(s)Cesar Rodriguez, MD, Frits van Rhee, MD, PhD

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.

Episodes in this series

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 1 Frontline Treatment Landscape in Transplant-Eligible Patients with NDMM

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 2 Study Design of the PERSEUS Trial

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 3 Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 4 Adverse Event Considerations for DARA-VRd in NDMM

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 5 Key Takeaways on Recent Data from PERSEUS

EP. 6 MRD May Predict Improved Outcomes in Multiple Myeloma

EP. 6 MRD May Predict Improved Outcomes in Multiple Myeloma

Video content above is prompted by the following questions:

Please discuss the safety profile of D-VRd and some common AEs seen in clinical practice?
What are some considerations/best practices of proactive management of the associated AEs with D-VRd?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

September 29th, 2026

Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

September 27th, 2026

Applying the IMS/IMWG Definition of Cure in Community Myeloma Practice

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

September 26th, 2026

Managing Sustained MRD Negativity After Multiple Myeloma Therapy Ends

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

September 25th, 2026

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Trending on CancerNetwork

Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer

What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?

Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma

SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery

CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy